Al-Dawaa Medical Services Company (4163.SR)
SAR 79.8
(1.79%)
SAR 79.8
(1.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.39 Billion SAR | -0.21% |
| 2022 | 3.4 Billion SAR | 11.83% |
| 2021 | 3.04 Billion SAR | 25.09% |
| 2020 | 2.43 Billion SAR | 12.07% |
| 2019 | 2.16 Billion SAR | 1.12% |
| 2018 | 2.14 Billion SAR | -2.24% |
| 2017 | 2.19 Billion SAR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 3.56 Billion SAR | 4.92% |
| 2024 Q2 | 3.54 Billion SAR | -0.51% |
| 2023 Q4 | 3.39 Billion SAR | 1.17% |
| 2023 FY | 3.39 Billion SAR | -0.21% |
| 2023 Q3 | 3.35 Billion SAR | -3.61% |
| 2023 Q2 | 3.48 Billion SAR | -4.64% |
| 2023 Q1 | 3.65 Billion SAR | 7.31% |
| 2022 Q2 | 3.73 Billion SAR | 14.84% |
| 2022 FY | 3.4 Billion SAR | 11.83% |
| 2022 Q4 | 3.4 Billion SAR | -5.43% |
| 2022 Q3 | 3.59 Billion SAR | -3.75% |
| 2022 Q1 | 3.25 Billion SAR | 6.98% |
| 2021 Q1 | - SAR | -100.0% |
| 2021 FY | 3.04 Billion SAR | 25.09% |
| 2021 Q4 | 3.04 Billion SAR | 0.0% |
| 2021 Q2 | 2.47 Billion SAR | 0.0% |
| 2020 Q1 | - SAR | 0.0% |
| 2020 Q3 | 2.43 Billion SAR | 0.0% |
| 2020 Q4 | 2.43 Billion SAR | 0.0% |
| 2020 FY | 2.43 Billion SAR | 12.07% |
| 2019 FY | 2.16 Billion SAR | 1.12% |
| 2018 FY | 2.14 Billion SAR | -2.24% |
| 2017 FY | 2.19 Billion SAR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Middle East Pharmaceutical Industries Co. | 138.49 Million SAR | -2350.904% |
| Nahdi Medical Company | 2.9 Billion SAR | -16.706% |
| Al-Razi Medical Co. | 23.04 Million SAR | -14627.686% |
| Almujtama Alraida Medical Co. | 312.21 Million SAR | -987.233% |